52130-34-4

Basic information

• Product Name: 5-(3 4-DICHLOROPHENYL)FURFURAL 97
• Synonyms: 5-(3 4-DICHLOROPHENYL)FURFURAL 97;5-(3,4-DICHLORO-PHENYL)-FURAN-2-CARBALDEHYDE;5-(3,4-dichlorophenyl)-2-furaldehyde(SALTDATA: FREE);5-(3,4-Dichlorophenyl)furfural 97%
• CAS NO: 52130-34-4
• Molecular Formula: C₁₁H₆Cl₂O₂
• Molecular Weight: 241.07
• Product Categories: API intermediates;Building Blocks;Furans;FuransHeterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Aldehydes;Building Blocks;C10-C12;C8 to C11;C9 to C11;Carbonyl Compounds;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks;Organic Building Blocks
• Mol File: 52130-34-4.mol
• Article Data: 11

Chemical Properties

• Melting Point: 140-143 °C(lit.)
• Boiling Point: 382.9°Cat760mmHg
• Flash Point: 185.4°C
• Appearance: /
• Density: 1.392g/cm³
• Vapor Pressure: 4.57E-06mmHg at 25°C
• Refractive Index: 1.605
• CAS DataBase Reference: 5-(3 4-DICHLOROPHENYL)FURFURAL 97(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3 4-DICHLOROPHENYL)FURFURAL 97(52130-34-4)
• EPA Substance Registry System: 5-(3 4-DICHLOROPHENYL)FURFURAL 97(52130-34-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 52130-34-4(Hazardous Substances Data)

Usage

General Description

5-(3,4-Dichlorophenyl)furfural is a chemical compound with the molecular formula C10H5Cl2O2. It is a yellow crystalline powder that is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 5-(3,4-Dichlorophenyl)furfural is also known for its potential application as a precursor in the preparation of various compounds used in the pharmaceutical and medical industries. Additionally, it is used in the manufacturing of perfumes and flavoring agents. However, it is important to handle this chemical with care, as it is known to be toxic if ingested, inhaled, or in contact with the skin.

InChI:InChI=1/C11H6Cl2O2/c12-9-3-1-7(5-10(9)13)11-4-2-8(6-14)15-11/h1-6H

Upstream product

• 98-01-1 furfural 
• 95-76-1 m,p-dichloroaniline 
• 18282-59-2 4-bromo-1,2-dichlorobenzene 
• 1899-24-7 5-bromo-2-furancarboxaldehyde 
• 27329-70-0 5-formylfurane-2-boronic acid 
• 20555-91-3 3,4-dichloroiodobenzene 
• 151169-75-4 3,4-dichlophenylboronic acid 

Downstream Products

• 311783-44-5 BI-11C3 
• 1191052-41-1 (Z)-methyl 4-(3-((5-(3,4-dichlorophenyl)furan-2-yl)methylene)-2-oxo-5-phenyl-2,3-dihydro-1H-pyrrol-1-yl)benzoate 
• 1427537-86-7 PFTA-1 
• 54023-01-7 5-(3,4-dichlorophenyl)furan-2-carboxylic acid 

Relevant articles and documents

Derivatives of (R)-3-(5-Furanyl)carboxamido-2-aminopropanoic Acid as Potent NMDA Receptor Glycine Site Agonists with GluN2 Subunit-Specific Activity

NMDA receptors mediate glutamatergic neurotransmission and are therapeutic targets due to their involvement in a variety of psychiatric and neurological disorders. Here, we describe the design and synthesis of a series of (R)-3-(5-furanyl)carboxamido-2-am

Identification of a small molecule inhibitor that stalls splicing at an early step of spliceosome activation

Small molecule inhibitors of pre-mRNA splicing are important tools for identifying new spliceosome assembly intermediates, allowing a finer dissection of spliceosome dynamics and function. Here, we identified a small molecule that inhibits human pre-mRNA splicing at an intermediate stage during conversion of pre-catalytic spliceosomal B complexes into activated Bact complexes. Characterization of the stalled complexes (designated B028) revealed that U4/U6 snRNP proteins are released during activation before the U6 Lsm and B-specific proteins, and before recruitment and/or stable incorporation of Prp19/CDC5L complex and other Bact complex proteins. The U2/U6 RNA network in B028 complexes differs from that of the Bact complex, consistent with the idea that the catalytic RNA core forms stepwise during the B to Bact transition and is likely stabilized by the Prp19/CDC5L complex and related proteins. Taken together, our data provide new insights into the RNP rearrangements and extensive exchange of proteins that occurs during spliceosome activation.

Novel inhibitors of Plasmodium falciparum based on 2,5-disubstituted furans

Phenotypic HTS campaigns with a blood stage malaria assay have been used to discover novel chemotypes for malaria treatment with potential alternative mechanisms of action compared to existing agents. N1-(5-(3-Chloro-4-fluorophenyl)furan-2-yl)-N3,N3-dimethylpropane-1,3-diamine, 1 was identified as a modest inhibitor of P. falciparum NF54 (IC50= 875 nM) with an apparent long plasma half-life after high dose oral administration to mice, although the compound later showed poor metabolic stability in liver microsomes through ring- and side chain-oxidation and N-dealkylation. We describe here the synthesis of derivatives of 1, exploring the influence of substitution patterns around the aromatic ring, variations on the alkyl chain and modifications in the core heterocycle, in order to probe potency and metabolic stability, where 4k showed a long half-life in rats.